Pharmaceutical giant Teva agreed to buy Allergan’s generic drug arm for about $US40.5 billion on Monday.
That should cement the Israel-based company’s position as the top generic drugmaker in the world.
It will also be great for Wall Street banks, which will reap millions in advisory and other fees.
Irish-based Actavis last year bought Allergan for $US66 billion, and kept the name.
Together, those two firms have generated some $US780 million in investment banking fees for mergers and acquisition advice and equity, debt and loan deals since 2012, according to consultant Freeman & Co.
Now, the Teva deal should boost total Allergan-Actavis fees to about $US820 million, according to Freeman, with Allergan adviser JPMorgan in line to receive between $US35 million and $US45 million in fees.
Barclays and Greenhill, which are advising Teva, should earn somewhere between $US30 million to $US40 million for the deal, Freeman estimated. That doesn’t include all the potential fees to come depending on the size and structure of the equity and debt package.
Business Insider Emails & Alerts
Site highlights each day to your inbox.